U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06840769) titled 'A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 Mg and Metabolites in Healthy Volunteers' on Feb. 11.
Brief Summary: This clinical trial will include two parts, i.e., Part A and Part B.
The goal of the Part A is to define the shortest safe and tolerable duration of an intravenous injection of Fosnetupitant 235 mg solution among 4 durations tested in male and female adult healthy volunteers. In study part A, researchers will compare Fosnetupitant 235 mg solution to Akynzeo(R) solution.
The duration determined in Part A will be investigated in study Part B.
The Part B of the study was not performed.
Stu...